Evidence map›Paper›PMID 35403852›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2022

Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation.

Marc Girod, Michael Coslovsky, Stefanie Aeschbacher, Christian Sticherling, Tobias Reichlin, Laurent Roten, Nicolas Rodondi, Peter Ammann, Angelo Auricchio, Giorgio Moschovitis and 14 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02105844 (Swiss Atrial Fibrillation Cohort Study - SWISS AF), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02105844 active not recruitingnot on this map

Swiss Atrial Fibrillation Cohort Study - SWISS AF

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2014 to 2030Enrolled2,415ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Marc GirodCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-7696-9948
Michael CoslovskyCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie AeschbacherCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Christian SticherlingCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Tobias ReichlinDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Laurent RotenDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas RodondiInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Peter AmmannDepartment of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Angelo AuricchioDivision of Cardiology, Institute Cardiocentro Ticino, Lugano, Switzerland.
Giorgio MoschovitisDivision of Cardiology, Ente Ospedaliero Cantonale, Regional Hospital of Lugano, Lugano, Switzerland.
Richard KobzaDepartment of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland.
Patrick BadertscherCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Sven KnechtCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Philipp KrisaiCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Andrea MaruggCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Helena AebersoldEpidemiology, Biostatistics, and Prevention Institute, University of Zürich, Zürich, Switzerland.
Elisa HenningsCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Miquel Serra-BurrielEpidemiology, Biostatistics, and Prevention Institute, University of Zürich, Zürich, Switzerland.
Matthias SchwenkglenksEpidemiology, Biostatistics, and Prevention Institute, University of Zürich, Zürich, Switzerland.
Christine S ZuernCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Leo H BonatiDepartment of Neurology and Stroke Center, University Hospital Basel, University of Basel, Basel, Switzerland.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Canada.
Stefan OsswaldCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael KühneCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. michael.kuehne@usb.ch.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 32473B_176178Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 33CS30_148474Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 33CS30_177520
6 · The paper itself

Abstract

backgroundPatients with atrial fibrillation (AF) face an increased risk of adverse cardiovascular events. Evidence suggests that early rhythm control including AF ablation may reduce this risk.

methodsTo compare the risks for cardiovascular events in AF patients with and without pulmonary vein isolation (PVI), we analysed data from two prospective cohort studies in Switzerland (n = 3968). A total of 325 patients who had undergone PVI during a 1-year observational period were assigned to the PVI group. Using coarsened exact matching, 2193 patients were assigned to the non-PVI group. Outcomes were all-cause mortality, hospital admission for acute heart failure, a composite of stroke, transient ischemic attack and systemic embolism (Stroke/TIA/SE), myocardial infarction (MI), and bleedings. We calculated multivariable adjusted Cox proportional-hazards models.

resultsOverall, 2518 patients were included, median age was 66 years [IQR 61.0, 71.0], 25.8% were female. After a median follow-up time of 3.9 years, fewer patients in the PVI group died from any cause (incidence per 100 patient-years 0.64 versus 1.87, HR 0.39, 95%CI 0.19-0.79, p = 0.009) or were admitted to hospital for acute heart failure (incidence per 100 patient-years 0.52 versus 1.72, HR 0.44, 95%CI 0.21-0.95, p = 0.035). There was no significant association between PVI and Stroke/TIA/SE (HR 0.94, 95%CI 0.52-1.69, p = 0.80), MI (HR 0.43, 95%CI 0.11-1.63, p = 0.20) or bleeding (HR 0.75, 95% CI 0.50-1.12, p = 0.20).

conclusionsIn our matched comparison, patients in the PVI group had a lower incidence rate of all-cause mortality and hospital admission for acute heart failure compared to the non-PVI group. CLINICALTRIALS: GOV IDENTIFIER: NCT02105844, April 7th 2014.

Indexed as

Atrial FibrillationCatheter AblationHeart FailureIschemic Attack, TransientPulmonary VeinsStrokeAgedFemaleHumansMaleProspective StudiesRecurrenceTreatment OutcomeAdverse outcome eventsAtrial fibrillationCoarsened exact matchingPulmonary vein isolation

Identifiers

PMID35403852
PMCPMC9424150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.